{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:36:55Z","timestamp":1774532215405,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":103,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783642029110","type":"print"},{"value":"9783642029127","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009]]},"DOI":"10.1007\/7854_2009_3","type":"book-chapter","created":{"date-parts":[[2009,9,16]],"date-time":"2009-09-16T07:22:59Z","timestamp":1253085779000},"page":"361-390","source":"Crossref","is-referenced-by-count":23,"title":["Antidepressant Treatment in Anxiety Disorders"],"prefix":"10.1007","author":[{"given":"Anton Y.","family":"Bespalov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel M.","family":"van Gaalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Gross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,9,17]]},"reference":[{"key":"3_CR1_3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1176\/appi.ajp.161.9.1642","volume":"161","author":"C Allgulander","year":"2004","unstructured":"Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM (2004) Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642\u20131649","journal-title":"Am J Psychiatry"},{"key":"3_CR2_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S146114570500578X","volume":"9","author":"C Allgulander","year":"2005","unstructured":"Allgulander C, Florea I, Trap Huusom AK (2005) Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:1\u201311","journal-title":"Int J Neuropsychopharmacol"},{"key":"3_CR3_3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1185\/03007998409109561","volume":"9","author":"LF Allsopp","year":"1984","unstructured":"Allsopp LF, Cooper GL, Poole PH (1984) Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Curr Med Res Opin 9:64\u201370","journal-title":"Curr Med Res Opin"},{"key":"3_CR4_3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/nn1399","volume":"8","author":"J Amat","year":"2005","unstructured":"Amat J, Baratta MV, Paul E, Bland ST, Watkins LR, Maier SF (2005) Medial prefrontal cortex determines how stressor controllability affects behavior and dorsal raphe nucleus. Nat Neurosci 8:365\u2013371","journal-title":"Nat Neurosci"},{"key":"3_CR5_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, M\u00f6ller HJ (2008) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders \u2013 first revision. World J Biol Psychiatry 9:248\u2013312","journal-title":"World J Biol Psychiatry"},{"key":"3_CR6_3","first-page":"59","volume-title":"5-HT1A agonists, 5-HT3 antagonists and benzodiazepines, their comparative behavioural pharmacology","author":"JE Barrett","year":"1991","unstructured":"Barrett JE, Gleeson S (1991) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: drug discrimination studies. In: Rodgers RJ, Cooper SJ (eds) 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines, their comparative behavioural pharmacology. Wiley, Chichester, pp 59\u2013105"},{"key":"3_CR7_3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1176\/appi.ajp.2008.08050721","volume":"165","author":"AT Beck","year":"2008","unstructured":"Beck AT (2008) The evolution of the cognitive model of depression and its neurobiological correlates. Am J Psychiatry 165:969\u2013977","journal-title":"Am J Psychiatry"},{"key":"3_CR8_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0166-4328(01)00291-1","volume":"125","author":"C Belzung","year":"2001","unstructured":"Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125:141\u2013149","journal-title":"Behav Brain Res"},{"key":"3_CR9_3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrn1846","volume":"7","author":"O Berton","year":"2006","unstructured":"Berton O, Nestler EJ (2006) New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7:137\u2013151","journal-title":"Nat Rev Neurosci"},{"key":"3_CR10_3","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1476-5381.1991.tb12342.x","volume":"103","author":"DJ Bill","year":"1991","unstructured":"Bill DJ, Knight M, Forster EA, Fletcher A (1991) Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia. Br J Pharmacol 103:1857\u20131864","journal-title":"Br J Pharmacol"},{"key":"3_CR11_3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nn.2242","volume":"12","author":"SJ Bishop","year":"2009","unstructured":"Bishop SJ (2009) Trait anxiety and impoverished prefrontal control of attention. Nat Neurosci 12:92\u201398","journal-title":"Nat Neurosci"},{"key":"3_CR12_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0014-2999(03)01276-7","volume":"463","author":"DC Blanchard","year":"2003","unstructured":"Blanchard DC, Griebel G, Blanchard RJ (2003) The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463:97\u2013116","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 15","key":"3_CR13_3","first-page":"12","volume":"62","author":"P Blier","year":"2001","unstructured":"Blier P (2001) Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 62(Suppl 15):12\u201317","journal-title":"J Clin Psychiatry"},{"key":"3_CR14_3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00213-002-1155-6","volume":"163","author":"F Borsini","year":"2002","unstructured":"Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163:121\u2013141","journal-title":"Psychopharmacology (Berl)"},{"key":"3_CR15_3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0006-8993(98)01350-X","volume":"819","author":"AW Bruijnzeel","year":"1999","unstructured":"Bruijnzeel AW, Stam R, Compaan JC, Croiset G, Akkermans LM, Olivier B, Wiegant VM (1999) Long-term sensitization of Fos-responsivity in the rat central nervous system after a single stressful experience. Brain Res 819:15\u201322","journal-title":"Brain Res"},{"key":"3_CR16_3","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","volume":"25","author":"FP Bymaster","year":"2001","unstructured":"Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871\u2013880","journal-title":"Neuropsychopharmacology"},{"key":"3_CR17_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2003.11.032","volume":"485","author":"S Chaki","year":"2004","unstructured":"Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T (2004) Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995\/CRA0450. Eur J Pharmacol 485:145\u2013158","journal-title":"Eur J Pharmacol"},{"key":"3_CR18_3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0149-7634(83)90010-6","volume":"7","author":"P Cook","year":"1983","unstructured":"Cook P, Wallace M, Singer G (1983) A reinterpretation of schedule-induced behaviors based on a systematic analysis of behavior. Neurosci Biobehav Rev 7:97\u2013104","journal-title":"Neurosci Biobehav Rev"},{"key":"3_CR19_3","unstructured":"Coric V, Goddard A, Oren D, Pultz J, Dockens R, Wu X, Gentile K, Thomas M, D\u2019Souza B, Shekhar A, Stock E (2008) A randomized, double-blind, placebo-controlled and active comparator trial of pexacerfont, a corticotropin releasing factor receptor-1 antagonist, in the treatment of generalized anxiety disorder. Paper presented at 47th ACNP meeting, Scottsdale, Arizona, 7\u201311 December, 2008"},{"key":"3_CR20_3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1600-0447.2005.00529.x","volume":"111","author":"AA Dahl","year":"2005","unstructured":"Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T (2005) Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. Acta Psychiatr Scand 111:429\u2013435","journal-title":"Acta Psychiatr Scand"},{"key":"3_CR21_3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/da.10146","volume":"19","author":"JR Davidson","year":"2004","unstructured":"Davidson JR, Bose A, Korotzer A, Zheng H (2004) Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234\u2013240","journal-title":"Depress Anxiety"},{"key":"3_CR22_3","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0006-3223(99)00014-1","volume":"46","author":"PL Delgado","year":"1999","unstructured":"Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS (1999) Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 46:212\u2013220","journal-title":"Biol Psychiatry"},{"key":"3_CR23_3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/00004850-198801000-00005","volume":"3","author":"JA Boer Den","year":"1988","unstructured":"Den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59\u201374","journal-title":"Int Clin Psychopharmacol"},{"key":"3_CR24_3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/sj.mp.4001419","volume":"8","author":"MD Dobrossy","year":"2003","unstructured":"Dobrossy MD, Drapeau E, Aurousseau C, Le Moal M, Piazza PV, Abrous DN (2003) Differential effects of learning on neurogenesis: learning increases or decreases the number of newly born cells depending on their birth date. Mol Psychiatry 8:974\u2013982","journal-title":"Mol Psychiatry"},{"key":"3_CR25_3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/187152707780619353","volume":"6","author":"MR Drew","year":"2007","unstructured":"Drew MR, Hen R (2007) Adult hippocampal neurogenesis as target for the treatment of depression. CNS Neurol Disord Drug Targets 6:205\u2013218","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"3_CR26_3","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0031-9384(71)90209-5","volume":"6","author":"JL Falk","year":"1971","unstructured":"Falk JL (1971) The nature and determinants of adjunctive behavior. Physiol Behav 6:577\u2013588","journal-title":"Physiol Behav"},{"key":"3_CR27_3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0091-3057(98)00208-1","volume":"62","author":"SE File","year":"1999","unstructured":"File SE, Ouagazzal AM, Gonzalez LE, Overstreet DH (1999) Chronic fluoxetine in tests of anxiety in rat lines selectively bred for differential 5-HT1A receptor function. Pharmacol Biochem Behav 62:695\u2013701","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR28_3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.2165\/00023210-199503060-00005","volume":"3","author":"NA Fineberg","year":"1995","unstructured":"Fineberg NA, Drummond LM (1995) Anxiety disorders: drug treatment of behavioral cognitive psychotherapy? CNS Drugs 3:448\u2013466","journal-title":"CNS Drugs"},{"issue":"Suppl 16","key":"3_CR29_3","first-page":"1","volume":"60","author":"EB Foa","year":"1999","unstructured":"Foa EB, Davidson JRT, Frances A (1999) The expert consensus guidelines series: treatment of posttraumatic stress disorder. J Clin Psychiatry 60(Suppl 16):1\u201376","journal-title":"J Clin Psychiatry"},{"key":"3_CR30_3","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMcp022342","volume":"351","author":"G Fricchione","year":"2004","unstructured":"Fricchione G (2004) Generalized anxiety disorder. N Engl J Med 351:675\u2013682","journal-title":"N Engl J Med"},{"key":"3_CR31_3","first-page":"216","volume":"54","author":"JP Garner","year":"2004","unstructured":"Garner JP, Weisker SM, Dufour B, Mench JA (2004) Barbering (fur and whisker trimming) by laboratory mice as a model of human trichotillomania and obsessive-compulsive spectrum disorders. Comp Med 54:216\u2013224","journal-title":"Comp Med"},{"key":"3_CR32_3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0278-5846(89)90132-2","volume":"13","author":"GM Goodwin","year":"1989","unstructured":"Goodwin GM (1989) The effects of antidepressant treatments and lithium upon 5-HT1A receptor function. Prog Neuropsychopharmacol Biol Psychiatry 13:445\u2013451","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3_CR33_3","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(95)98597-J","volume":"65","author":"G Griebel","year":"1995","unstructured":"Griebel G (1995) 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. Pharmacol Ther 65:319\u2013395","journal-title":"Pharmacol Ther"},{"key":"3_CR34_3","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02246145","volume":"120","author":"G Griebel","year":"1995","unstructured":"Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995) Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57\u201366","journal-title":"Psychopharmacology"},{"key":"3_CR35_3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/YIC.0b013e32807fb1b2","volume":"22","author":"J Hartford","year":"2007","unstructured":"Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J (2007) Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 22:167\u2013174","journal-title":"Int Clin Psychopharmacol"},{"key":"3_CR36_3","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.pnpbp.2008.10.015","volume":"33","author":"S Hashimoto","year":"2009","unstructured":"Hashimoto S, Inoue T, Muraki I, Koyama T (2009) Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog Neuropsychopharmacol Biol Psychiatry 33:113\u2013117","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3_CR37_3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ajmg.c.30171","volume":"148C","author":"JM Hettema","year":"2008","unstructured":"Hettema JM (2008) What is the genetic relationship between anxiety and depression? Am J Med Genet Part C Semin Med Genet 148C:140\u2013147","journal-title":"Am J Med Genet Part C Semin Med Genet"},{"key":"3_CR38_3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2007.09.005","volume":"88","author":"RA Hodgson","year":"2008","unstructured":"Hodgson RA, Guthrie DH, Varty GB (2008) Duration of ultrasonic vocalizations in the isolated rat pup as a behavioral measure: sensitivity to anxiolytic and antidepressant drugs. Pharmacol Biochem Behav 88:341\u2013348","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR39_3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/msj.20041","volume":"75","author":"EJ Hoffman","year":"2008","unstructured":"Hoffman EJ, Mathew SJ (2008) Anxiety disorders: a comprehensive review of pharmacotherapies. Mount Sinai J Med 75:248\u2013262","journal-title":"Mount Sinai J Med"},{"key":"3_CR40_3","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pbb.2003.09.020","volume":"77","author":"S Hogg","year":"2004","unstructured":"Hogg S, Dalvi A (2004) Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT(1A) and 5-HT(1B) receptor antagonists. Pharmacol Biochem Behav 77:69\u201375","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR41_3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuropharm.2006.03.009","volume":"51","author":"S Hogg","year":"2006","unstructured":"Hogg S, Michan L, Jessa M (2006) Prediction of anti-panic properties of escitalopram in the dorsal periaqueductal grey model of panic anxiety. Neuropharmacology 51:141\u2013145","journal-title":"Neuropharmacology"},{"key":"3_CR42_3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2006.04.013","volume":"540","author":"T Inoue","year":"2006","unstructured":"Inoue T, Nakagawa S, Izumi T, Kitaichi Y, Koyama T (2006) Effect of combined treatment with noradrenaline and serotonin reuptake inhibitors on conditioned freezing. Eur J Pharmacol 540:91\u201395","journal-title":"Eur J Pharmacol"},{"key":"3_CR43_3","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/sj.npp.1301328","volume":"32","author":"M Ising","year":"2007","unstructured":"Ising M, Zimmermann US, K\u00fcnzel HE, Uhr M, Foster AC, Learned-Coughlin SM, Holsboer F, Grigoriadis DE (2007) High-affinity CRF1 receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32:1941\u20131949","journal-title":"Neuropsychopharmacology"},{"key":"3_CR44_3","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.pnpbp.2005.11.006","volume":"30","author":"D Joel","year":"2006","unstructured":"Joel D (2006) Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 30:374\u2013388","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3_CR45_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00008877-200211000-00002","volume":"13","author":"N Jones","year":"2002","unstructured":"Jones N, King SM, Duxon MS (2002) Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: differential effects of fluoxetine and chlordiazepoxide. Behav Pharmacol 13:525\u2013535","journal-title":"Behav Pharmacol"},{"key":"3_CR46_3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0165-0327(87)90019-X","volume":"13","author":"RJ Kahn","year":"1987","unstructured":"Kahn RJ, McNair DM, Frankenthaler LM (1987) Tricyclic treatment of generalized anxiety disorder. J Affect Disord 13:145\u2013151","journal-title":"J Affect Disord"},{"key":"3_CR47_3","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1056\/NEJMcp052466","volume":"354","author":"WJ Katon","year":"2006","unstructured":"Katon WJ (2006) Panic disorder. N Engl J Med 354:2360\u20132367","journal-title":"N Engl J Med"},{"key":"3_CR48_3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00008877-199912000-00007","volume":"10","author":"AJ Keeney","year":"1999","unstructured":"Keeney AJ, Hogg S (1999) Behavioural consequences of repeated social defeat in the mouse: preliminary evaluation of a potential animal model of depression. Behav Pharmacol 10:753\u2013764","journal-title":"Behav Pharmacol"},{"key":"3_CR49_3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/archpsyc.62.6.593","volume":"62","author":"RC Kessler","year":"2005","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593\u2013602","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR50_3","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0091-3057(94)90422-7","volume":"49","author":"S Lightowler","year":"1994","unstructured":"Lightowler S, Kennett GA, Williamson IJ, Blackburn TP, Tulloch IF (1994) Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49:281\u2013285","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR51_3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1176\/appi.ajp.2007.06091513","volume":"165","author":"S Lissek","year":"2008","unstructured":"Lissek S, Levenson J, Biggs AL, Johnson LL, Ameli R, Pine DS, Grillon C (2008) Elevated fear conditioning to socially relevant unconditioned stimuli in social anxiety disorder. Am J Psychiatry 165:124\u2013132","journal-title":"Am J Psychiatry"},{"key":"3_CR52_3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1073\/pnas.0807041106","volume":"106","author":"C Liston","year":"2009","unstructured":"Liston C, McEwen BS, Casey BJ (2009) Psychosocial stress reversibly disrupts prefrontal processing and attentional control. Proc Natl Acad Sci USA 106:912\u2013917","journal-title":"Proc Natl Acad Sci USA"},{"key":"3_CR53_3","doi-asserted-by":"crossref","first-page":"7870","DOI":"10.1523\/JNEUROSCI.1184-06.2006","volume":"26","author":"C Liston","year":"2006","unstructured":"Liston C, Miller MM, Goldwater DS, Radley JJ, Rocher AB, Hof PR, Morrison JH, McEwen BS (2006) Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting. J Neurosci 26:7870\u20137874","journal-title":"J Neurosci"},{"key":"3_CR54_3","first-page":"183","volume":"29","author":"RB Lydiard","year":"1993","unstructured":"Lydiard RB, Morton WA, Emmanuel NP, Zealberg JJ, Laraia MT, Stuart GW, O\u2019Neil PM, Ballenger JC (1993) Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29:183\u2013188","journal-title":"Psychopharmacol Bull"},{"key":"3_CR55_3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2005.08.020","volume":"82","author":"E Malatynska","year":"2005","unstructured":"Malatynska E, Rapp R, Harrawood D, Tunnicliff G (2005) Submissive behavior in mice as a test for antidepressant drug activity. Pharmacol Biochem Behav 82:306\u2013313","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR56_3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0165-0327(96)00081-X","volume":"41","author":"GG Manfro","year":"1996","unstructured":"Manfro GG, Otto MW, McArdle ET, Worthington JJ III, Rosenbaum JF, Pollack MH (1996) Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord 41:135\u2013139","journal-title":"J Affect Disord"},{"key":"3_CR57_3","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1176\/appi.ajp.158.12.1982","volume":"158","author":"RD Marshall","year":"2001","unstructured":"Marshall RD, Beebe KL, Oldham M, Zaninelli R (2001) Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo- controlled study. Am J Psychiatry 158:1982\u20131988","journal-title":"Am J Psychiatry"},{"key":"3_CR58_3","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/FBP.0b013e3282ee82e3","volume":"18","author":"N McNaughton","year":"2007","unstructured":"McNaughton N, Kocsis B, Hajos M (2007) Elicited hippocampal theta rhythm: a screen for anxiolytic and procognitive drugs through changes in hippocampal function? Behav Pharmacol 18:329\u2013346","journal-title":"Behav Pharmacol"},{"key":"3_CR59_3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2005.09.029","volume":"526","author":"PJ Mitchell","year":"2005","unstructured":"Mitchell PJ (2005) Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526:147\u2013162","journal-title":"Eur J Pharmacol"},{"key":"3_CR60_3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/npp.1994.6","volume":"10","author":"R Mongeau","year":"1994","unstructured":"Mongeau R, de Montigny C, Blier P (1994) Electrophysiologic evidence for desensitization of alpha 2-adrenoceptors on serotonin terminals following long-term treatment with drugs increasing norepinephrine synaptic concentration. Neuropsychopharmacology 10:41\u201351","journal-title":"Neuropsychopharmacology"},{"key":"3_CR61_3","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.4088\/JCP.v66n1009","volume":"66","author":"SA Montgomery","year":"2005","unstructured":"Montgomery SA, Nil R, D\u00fcrr-Pal N, Loft H, Boulenger JP (2005) A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270\u20131278","journal-title":"J Clin Psychiatry"},{"key":"3_CR62_3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(87)90648-0","volume":"142","author":"T Nagatani","year":"1987","unstructured":"Nagatani T, Yamamoto T, Sugihara T, Ueki S (1987) The effect of agonists at the GABA-benzodiazepine receptor complex on the duration of immobility of mice in the forced swimming test. Eur J Pharmacol 142:17\u201322","journal-title":"Eur J Pharmacol"},{"key":"3_CR63_3","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.biopsych.2004.12.039","volume":"57","author":"T Nakao","year":"2005","unstructured":"Nakao T, Nakagawa A, Yoshiura T, Nakatani E, Nabeyama M, Yoshizato C, Kudoh A, Tada K, Yoshioka K, Kawamoto M, Togao O, Kanba S (2005) Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 57:901\u2013910","journal-title":"Biol Psychiatry"},{"key":"3_CR64_3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1901\/jeab.2001.76-43","volume":"76","author":"JA Nevin","year":"2001","unstructured":"Nevin JA, Grace RC, Holland S, McLean AP (2001) Variable-ratio versus variable-interval schedules: Response rate, resistance to change, and preference. J Exp Anal Behav 76:43\u201374","journal-title":"J Exp Anal Behav"},{"issue":"Suppl 17","key":"3_CR65_3","first-page":"4","volume":"59","author":"DJ Nutt","year":"1998","unstructured":"Nutt DJ, Bell CJ, Malizia AL (1998) Brain mechanisms of social anxiety disorder. J Clin Psychiatry 59(Suppl 17):4\u201311","journal-title":"J Clin Psychiatry"},{"key":"3_CR66_3","first-page":"661","volume":"10","author":"JP Oli\u00e9","year":"2007","unstructured":"Oli\u00e9 JP, Kasper S (2007) Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 10:661\u2013673","journal-title":"Int J Neuropsychopharmacol"},{"key":"3_CR67_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/da.20218","volume":"24","author":"MH Pollack","year":"2007","unstructured":"Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G, Tzanis E, Salinas E, Whitaker T, Gao B (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24:1\u201314","journal-title":"Depress Anxiety"},{"key":"3_CR68_3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.neuron.2008.07.041","volume":"60","author":"DD Pollak","year":"2008","unstructured":"Pollak DD, Monje FJ, Zuckerman L, Denny CA, Drew MR, Kandel ER (2008) An animal model of a behavioral intervention for depression. Neuron 60:149\u2013161","journal-title":"Neuron"},{"key":"3_CR69_3","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/266730a0","volume":"266","author":"RD Porsolt","year":"1977","unstructured":"Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266:730\u2013732","journal-title":"Nature"},{"key":"3_CR70_3","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1176\/appi.ajp.157.12.1973","volume":"157","author":"K Rickels","year":"2000","unstructured":"Rickels K, DeMartinis N, Garcia-Espana F (2000) Imipramine and buspirone in treatment of patients with generalized anxiety disorder for discontinuing long-term benzodiazepine therapy. Am J Psychiatry 157:1973\u20131979","journal-title":"Am J Psychiatry"},{"key":"3_CR71_3","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/archpsyc.1993.01820230054005","volume":"50","author":"K Rickels","year":"1993","unstructured":"Rickels K, Downing R, Schweizer E, Hassman H (1993) Antidepressants for the treatment of generalized anxiety disorder: a placebo controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884\u2013895","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR72_3","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.160.4.749","volume":"160","author":"K Rickels","year":"2003","unstructured":"Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749\u2013756","journal-title":"Am J Psychiatry"},{"key":"3_CR73_3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","volume":"113","author":"S Rosenzweig-Lipson","year":"2007","unstructured":"Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, Schechter LE (2007) Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113:134\u2013153","journal-title":"Pharmacol Ther"},{"key":"3_CR74_3","first-page":"R776","volume":"272","author":"H Rupp","year":"1997","unstructured":"Rupp H, Maisch B, Brilla CG (1997) Schedule-induced psychological stress and molecular structures of cardiomyocytes. Am J Physiol 272:R776\u2013R782","journal-title":"Am J Physiol"},{"key":"3_CR75_3","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJMcp060145","volume":"355","author":"FR Schneier","year":"2006","unstructured":"Schneier FR (2006) Social anxiety disorder. N Engl J Med 355:1029\u20131036","journal-title":"N Engl J Med"},{"key":"3_CR76_3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1600-0447.2004.00502.x","volume":"111","author":"K Schruers","year":"2005","unstructured":"Schruers K, Koning K, Luermans J, Haack MJ, Griez E (2005) Obsessive-compulsive disorder: a critical review of therapeutic perspectives. Acta Psychiatr Scand 111:261\u2013271","journal-title":"Acta Psychiatr Scand"},{"key":"3_CR77_3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archpsyc.1980.01780140053006","volume":"37","author":"DV Sheehan","year":"1980","unstructured":"Sheehan DV, Ballenger J, Jacobsen G (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37:51\u201359","journal-title":"Arch Gen Psychiatry"},{"key":"3_CR78_3","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0091-3057(82)90451-8","volume":"16","author":"AD Sherman","year":"1982","unstructured":"Sherman AD, Sacquitne JL, Petty F (1982) Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 16:449\u2013454","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR79_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00004714-199804000-00005","volume":"18","author":"HB Simpson","year":"1998","unstructured":"Simpson HB, Schneier FR, Campeas RB, Marshall RD, Fallon BA, Davies S, Klein DF, Liebowitz MR (1998) Imipramine in the treatment of social phobia. J Clin Psychopharmacol 18:132\u2013135","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR80_3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/0091-3057(89)90242-6","volume":"32","author":"B Soderpalm","year":"1989","unstructured":"Soderpalm B, Hjorth S, Engel JA (1989) Effects of 5-HT1A receptor agonists and L-5-HTP in Montgomery\u2019s conflict test. Pharmacol Biochem Behav 32:259\u2013265","journal-title":"Pharmacol Biochem Behav"},{"key":"3_CR81_3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s002130051155","volume":"147","author":"JD Sokolowski","year":"1999","unstructured":"Sokolowski JD, Seiden LS (1999) The behavioral effects of sertraline, fluoxetine, and paroxetine differ on the differential-reinforcement-of-low-rate 72-second operant schedule in the rat. Psychopharmacology 147:153\u2013161","journal-title":"Psychopharmacology"},{"key":"3_CR82_3","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.neubiorev.2007.01.001","volume":"31","author":"R Stam","year":"2007","unstructured":"Stam R (2007) PTSD and stress sensitisation: A tale of brain and body. Part 2: animal models. Neurosci Biobehav Rev 31:558\u2013584","journal-title":"Neurosci Biobehav Rev"},{"key":"3_CR83_3","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-02912-7_14","author":"T Steckler","year":"2009","unstructured":"Steckler T (2009) Developing small molecule non-peptidergic drugs for the treatment of anxiety disorders \u2013 is the challenge still ahead? Curr Top Behav Neurosci. doi: 10.1007\/978-3-642-02912-7_14","journal-title":"Curr Top Behav Neurosci"},{"key":"3_CR84_3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/JCP.0b013e318184ff5b","volume":"28","author":"DJ Stein","year":"2008","unstructured":"Stein DJ, Ahokas AA, de Bodinat C (2008) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol 28:561\u2013566","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR85_3","first-page":"CD001206","volume":"4","author":"DJ Stein","year":"2004","unstructured":"Stein DJ, Ipser JC, Balkom AJ (2004) Pharmacotherapy for social phobia. Cochrane Database Syst Rev 4:CD001206","journal-title":"Cochrane Database Syst Rev"},{"key":"3_CR86_3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","volume":"177","author":"MB Stein","year":"2005","unstructured":"Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM (2005) Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology 177:280\u2013288","journal-title":"Psychopharmacology"},{"key":"3_CR87_3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","volume":"371","author":"MB Stein","year":"2008","unstructured":"Stein MB, Stein DJ (2008) Social anxiety disorder. Lancet 371:1115\u20131125","journal-title":"Lancet"},{"key":"3_CR88_3","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1523\/JNEUROSCI.14-05-02579.1994","volume":"14","author":"MP Stenzel-Poore","year":"1994","unstructured":"Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob GF, Vale WW (1994) Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 14:2579\u20132584","journal-title":"J Neurosci"},{"key":"3_CR89_3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4088\/JCP.v64n0305","volume":"64","author":"F Stocchi","year":"2003","unstructured":"Stocchi F, Nordera G, Jokinen RH, Lepola UM, Hewett K, Bryson H, Iyengar MK (2003) Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 64:250\u2013258","journal-title":"J Clin Psychiatry"},{"key":"3_CR90_3","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/syn.10009","volume":"42","author":"ST Szabo","year":"2001","unstructured":"Szabo ST, Blier P (2001) Serotonin (1A) receptor ligands act on norepinephrine neuron firing through excitatory amino acid and GABA(A) receptors: a microiontophoretic study in the rat locus coeruleus. Synapse 42:203\u2013212","journal-title":"Synapse"},{"key":"3_CR91_3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/sj.bjp.0702343","volume":"126","author":"ST Szabo","year":"1999","unstructured":"Szabo ST, de Montigny C, Blier P (1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 126:568\u2013571","journal-title":"Br J Pharmacol"},{"key":"3_CR92_3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00432516","volume":"87","author":"MH Thiebot","year":"1985","unstructured":"Thiebot MH, Soubrie P, Simon P (1985) Is delay of reward mediated by shock-avoidance behavior a critical target for anti-punishment effects of diazepam in rats? Psychopharmacology (Berl) 87:473\u2013479","journal-title":"Psychopharmacology (Berl)"},{"key":"3_CR93_3","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nn1919","volume":"10","author":"T Tsetsenis","year":"2007","unstructured":"Tsetsenis T, Ma XH, Lo IL, Beck SG, Gross C (2007) Suppression of conditioning to ambiguous cues by pharmacogenetic inhibition of the dentate gyrus. Nat Neurosci 10:896\u2013902","journal-title":"Nat Neurosci"},{"issue":"Suppl 6","key":"3_CR94_3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0924-977X(99)00050-4","volume":"9","author":"EH Uhlenhuth","year":"1999","unstructured":"Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999a) Trends in recommendations for the pharmacotherapy of anxiety disorders by an international expert panel, 1992\u20131997. Eur Neuropsychopharmacol 9(Suppl 6):393\u2013398","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl 2","key":"3_CR95_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/00004714-199912002-00005","volume":"19","author":"EH Uhlenhuth","year":"1999","unstructured":"Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999b) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disorders. J Clin Psychopharmacol 19(Suppl 2):23\u201329","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR96_3","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF02247714","volume":"109","author":"HH Dijken van","year":"1992","unstructured":"van Dijken HH, Tilders FJH, Olivier B, Mos J (1992) Effect of anxiolytic and antidepressant drugs on long-lasting behavioural deficits resulting from one short stress experience in male rats. Psychopharmacology 109:395\u2013402","journal-title":"Psychopharmacology"},{"key":"3_CR97_3","unstructured":"Van Gaalen MM (2001) Long-term alterations in the corticotrophin-releasing hormone system: effects on emotional function and attention. PhD thesis, Max Planck Institute of Psychiatry, Munich, Germany"},{"key":"3_CR98_3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4088\/JCP.v63n0107","volume":"63","author":"M Versiani","year":"2002","unstructured":"Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31\u201337","journal-title":"J Clin Psychiatry"},{"key":"3_CR99_3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00004714-198808000-00008","volume":"8","author":"M Versiani","year":"1988","unstructured":"Versiani M, Mundim FD, Nardi AE, Liebowitz MR (1988) Tranylcypromine in social phobia. J Clin Psychopharmacol 8:279\u2013283","journal-title":"J Clin Psychopharmacol"},{"key":"3_CR100_3","first-page":"257","volume-title":"Central and peripheral 5-HT3 receptors","author":"JP Wettstein","year":"1992","unstructured":"Wettstein JP (1992) 5-HT3 receptor ligands as potential anxiolytics. In: Hamon M (ed) Central and peripheral 5-HT3 receptors. Academic, London, pp 257\u2013274"},{"key":"3_CR101_3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/BF02244228","volume":"101","author":"S Wieland","year":"1990","unstructured":"Wieland S, Lucki I (1990) Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101:497\u2013504","journal-title":"Psychopharmacology"},{"key":"3_CR102_3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0893-133X(02)00307-X","volume":"27","author":"MC Wolff","year":"2002","unstructured":"Wolff MC, Leander JD (2002) Selective serotonin reuptake inhibitors decrease impulsive behavior as measured by an adjusting delay procedure in the pigeon. Neuropsychopharmacology 27:421\u2013429","journal-title":"Neuropsychopharmacology"},{"key":"3_CR103_3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0006-8993(99)02289-1","volume":"855","author":"Y Zhang","year":"2000","unstructured":"Zhang Y, Raap DK, Garcia F, Serres F, Ma Q, Battaglia G, Van de Kar LD (2000) Long-term fluoxetine produces behavioral anxiolytic effects without inhibiting neuroendocrine responses to conditioned stress in rats. Brain Res 855:58\u201366","journal-title":"Brain Res"}],"container-title":["Current Topics in Behavioral Neurosciences","Behavioral Neurobiology of Anxiety and Its Treatment"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/7854_2009_3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,9]],"date-time":"2019-03-09T13:15:43Z","timestamp":1552137343000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/7854_2009_3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009]]},"ISBN":["9783642029110","9783642029127"],"references-count":103,"URL":"https:\/\/doi.org\/10.1007\/7854_2009_3","relation":{},"ISSN":["1866-3370","1866-3389"],"issn-type":[{"value":"1866-3370","type":"print"},{"value":"1866-3389","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009]]}}}